1. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21:115–137.
Article
2. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008; 93:861–868.
Article
3. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001; 12:989–995.
Article
4. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014; 142:155–170.
Article
5. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005; 20:177–184.
Article
6. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000; 289:1508–1514.
Article
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423:337–342.
Article
8. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005; 57:389–395.
Article
9. Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014; 14:722–735.
Article
10. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3:889–901.
Article
11. Spribille T, Tuovinen V, Resl P, et al. Basidiomycete yeasts in the cortex of ascomycete macrolichens. Science. 2016; 353:488–492.
Article
12. Kellogg JJ, Raja HA. Endolichenic fungi: a new source of rich bioactive secondary metabolites on the horizon. Phytochem Rev. 2017; 16:271–293.
Article
13. Chen GD, Chen Y, Gao H, et al. Xanthoquinodins from the endolichenic fungal strain Chaetomium elatum. J Nat Prod. 2013; 76:702–709.
Article
14. Li XB, Zhou YH, Zhu RX, et al. Identification and biological evaluation of secondary metabolites from the endolichenic fungus Aspergillus versicolor. Chem Biodivers. 2015; 12:575–592.
Article
15. Kim KJ, Yeon JT, Choi SW, et al. Decursin inhibits osteoclastogenesis by downregulating NFATc1 and blocking fusion of pre-osteoclasts. Bone. 2015; 81:208–216.
Article
16. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000; 132:365–386.
Article
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–408.
Article
18. Kim H, Kim KJ, Yeon JT, et al. Placotylene A, an inhibitor of the receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation, from a Korean sponge Placospongia sp. Mar Drugs. 2014; 12:2054–2065.
Article
19. Kim KJ, Lee Y, Hwang HG, et al. Betulin suppresses osteoclast formation via down-regulating NFATc1. J Clin Med. 2018; 7:154.
Article
20. Girlanda M, Isocrono D, Bianco C, et al. Two foliose lichens as microfungal ecological niches. Mycologia. 1997; 89:531–536.
Article
21. Li XB, Li L, Zhu RX, et al. Tetramic acids and pyridone alkaloids from the endolichenic fungus tolypocladium cylindrosporum. J Nat Prod. 2015; 78:2155–2160.
Article
22. Wu W, Dai H, Bao L, et al. Isolation and structural elucidation of proline-containing cyclopentapeptides from an endolichenic Xylaria sp. J Nat Prod. 2011; 74:1303–1308.
Article
23. Wijeratne EM, Bashyal BP, Liu MX, et al. Geopyxins A-E, ent-kaurane diterpenoids from endolichenic fungal strains Geopyxis aff. majalis and Geopyxis sp. AZ0066: structure-activity relationships of geopyxins and their analogues. J Nat Prod. 2012; 75:361–369.
Article
24. Wu YH, Chen GD, Wang CX, et al. Pericoterpenoid A, a new bioactive cadinane-type sesquiterpene from Periconia sp. J Asian Nat Prod Res. 2015; 17:671–675.
Article
25. Frisvad JC, Andersen B, Thrane U. The use of secondary metabolite profiling in chemotaxonomy of filamentous fungi. Mycol Res. 2008; 112:231–240.
Article
26. Parrot D, Jan S, Baert N, et al. Comparative metabolite profiling and chemical study of Ramalina siliquosa complex using LC-ESI-MS/MS approach. Phytochemistry. 2013; 89:114–124.
Article
27. Kim GS, Ko W, Kim JW, et al. Bioactive α-pyrone derivatives from the endolichenic fungus dothideomycetes sp. EL003334. J Nat Prod. 2018; 81:1084–1088.
Article
28. Kim JW, Ko W, Kim E, et al. Anti-inflammatory phomalichenones from an endolichenic fungus Phoma sp. J Antibiot (Tokyo). 2018; 71:753–756.
Article
29. Kim KJ, Jeong MH, Lee Y, et al. Effect of usnic acid on osteoclastogenic activity. J Clin Med. 2018; 7:345.
Article
30. Golob AL, Laya MB. Osteoporosis: screening, prevention, and management. Med Clin North Am. 2015; 99:587–606.
31. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011; 22:1835–1844.
Article
32. Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013; 8:137.
Article
33. Wade SW, Strader C, Fitzpatrick LA, et al. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014; 9:182.
Article
34. Yasuda H, Shima N, Nakagawa N, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 1999; 25:109–113.
Article
35. Sherr CJ. Colony-stimulating factor-1 receptor. Blood. 1990; 75:1–12.
Article
36. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993; 91:257–263.
Article
37. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7:292–304.
Article
38. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 1982; 34:285–290.
Article
39. Kim B, Kim HH, Lee ZH. α-Tocopheryl succinate inhibits osteolytic bone metastasis of breast cancer by suppressing migration of cancer cells and receptor activator of nuclear factor-κB ligand expression of osteoblasts. J Bone Metab. 2018; 25:23–33.
Article
40. Yagi M, Miyamoto T, Toyama Y, et al. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab. 2006; 24:355–358.
Article
41. Matsumoto M, Kogawa M, Wada S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem. 2004; 279:45969–45979.
Article